ALGS — Aligos Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1799448 ·
Last close
$1.36
Market Cap
$7.40M
52W High
$13.69
52W Low
$1.36
ADV30
60,191
Next earnings
2026-11-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 2,869,000 | — | -21,890,000 | -21,860,000 | 47,189,000 | 31,094,000 | 35,883,000 |
| Jun 2026 | 27,778,000 | — | -1,890,000 | -1,504,000 | 66,327,000 | 30,381,000 | 34,443,000 |
| Mar 2026 | 2,830,000 | — | -26,929,000 | -23,040,000 | 64,558,000 | 29,980,000 | 32,769,000 |
| Dec 2025 | 169,000 | — | -21,814,000 | -19,881,000 | 88,533,000 | 18,303,000 | 34,988,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-94,168,000
Investing CF
$105,592,000
Financing CF
$228,000
CapEx
$-355,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-7.30
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-666,745,000
Inventory
—
Receivables
$27,778,000
ST Investments
$0
EBIT TTM
$-78,994,000
Pretax Income TTM
$-72,748,000
Interest Exp TTM
—
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$31,518,000
EBITDA
$-77,916,000
Free Cash Flow
$-61,390,248
Enterprise Value
$-1,461,649
Total Cash
$30,381,000
Total Debt
$3,504,000
Shares Out
5,444,558
Trailing EPS
$-6.46
Book Value
$8.67
ROE
-113.6%
ROA
-49.1%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 2,186,000 | -87,985,000 | -24,193,000 | 88,533,000 | 34,988,000 | 53,545,000 | -82,503,000 |
| Dec 2024 | 3,945,000 | -89,154,000 | -131,211,000 | 70,094,000 | 99,067,000 | -28,973,000 | -80,743,000 |
| Dec 2023 | 15,529,000 | -88,127,000 | -87,679,000 | 151,527,000 | 59,447,000 | 92,080,000 | -78,997,000 |
| Dec 2022 | 13,907,000 | -97,580,000 | -96,046,000 | 146,693,000 | 42,793,000 | 103,900,000 | -79,389,000 |
TTM Snapshot
Revenues TTM
$3,740,000
NetIncome TTM
$-75,962,000
OpCashFlow TTM
—
Assets (Latest)
$66,327,000
Forward EPS
$-5.25
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CUBT | Curative Biotechnology Inc | $7.56M | $0.85 | — |
| ZEOX | Zeo ScientifiX, Inc. | $6.27M | $0.80 | — |
| INTS | INTENSITY THERAPEUTICS, INC. | $8.81M | $2.67 | — |
| INAB | IN8BIO, INC. | $8.86M | $0.82 | — |
| TCRX | TScan Therapeutics, Inc. | $9.59M | $0.15 | — |
News headlines (Yahoo Finance, 1h cache)
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results
2026-11-06 13:00 · Yahoo
Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2026
2026-11-05 21:05 · Yahoo
Aligos Therapeutics Announces Five Abstracts Accepted for Presentation at The Liver Meeting® 2026
2026-10-05 20:05 · Yahoo
Aligos Therapeutics Shares Rise 7.6% Premarket Following Recent Company Updates
2026-09-02 10:45 · Yahoo
Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China
2026-08-12 20:05 · Yahoo
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results
2026-08-06 12:00 · Yahoo
Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026
2026-07-30 12:00 · Yahoo
Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection
2026-07-13 12:00 · Yahoo
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-04-24 12:00 · Yahoo
Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026
2026-05-13 06:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.